Suda Tetsuji

写真a

Title

Instructor

Researcher Number(JSPS Kakenhi)

40423347

Current Affiliation Organization 【 display / non-display

  • Duty   University of the Ryukyus   Graduate School of Medicine   Instructor  

External Career 【 display / non-display

  • 2013.05
     
     

    - , University of the Ryukyus, Graduate School of Medicine, Instructor  

  • 2013.05
     
     

     

  • 2013.05
     
     

    University of the Ryukyus, Graduate School of Medicine, Instructor  

Research Areas 【 display / non-display

  • Life Science / Tumor biology

Published Papers 【 display / non-display

  • Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma

    Nakanishi, S; Goya, M; Suda, T; Yonamine, T; Sugawa, A; Saito, S

    BMC UROLOGY ( BMC Urology )  24 ( 1 ) 94   2024.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.

    Harada J, Miyata Y, Taima T, Matsuda T, Mukae Y, Mitsunari K, Matsuo T, Ohba K, Suda T, Sakai H, Ito A, Saito S

    Anticancer research ( Anticancer Research )  41 ( 7 ) 3327 - 3335   2021.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Collagen type 1A1, type 3A1, and LOXL1/4 polymorphisms as risk factors of pelvic organ prolapse.

    Ashikari A, Suda T, Miyazato M

    BMC research notes ( BMC Research Notes )  14 ( 1 ) 15   2021.01 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.

    Matsumura E, Kosuge N, Nakanishi S, Suda T, Sugawa A, Fujimura T, Miyagi R, Yoshimi N, Saito S

    The Tohoku journal of experimental medicine ( 東北ジャーナル刊行会 )  252 ( 3 ) 225 - 244   2020.11 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    <p>Urothelial carcinoma of the bladder (UCB) is potentially life-threatening; therefore, we aimed to discover a novel urine biomarker for diagnosis and prognostication of UCB. This is a retrospective case-control study. Exploration of a new biomarker using urine from 20 UCB patients in the present study revealed that urinary level of lactoferrin (LF), a multifunctional glycoprotein released from neutrophils, was higher in 11 of 15 with invasive/high-grade UCB than 5 with non-invasive one, and 2 healthy adults. We therefore focused on LF and assessed the value of urine LF normalized by urine creatinine concentration (LF/Cr) using an enzyme-linked immunosorbent assay. Diagnostic performance of urine LF/Cr was examined using urine from 92 patients with primary (newly diagnosed) untreated UCB and 166 controls without UCB, including 62 patients with pyuria, and 104 subjects without pyuria consisting of 84 patients and 20 healthy adults. However, the diagnostic accuracies were accompanied by the risk of bias. In 92 primary UCB patients, both pyuria and tumor-infiltrating neutrophils (TINs) were independent predictors for urine LF/Cr. In contrast, TINs or urine LF/Cr were independent predictors for invasive histology, whereas pyuria was not. In terms of prognostication, urine LF/Cr and nodal metastasis were independent predictors of disease-specific survival in 22 patients with muscle-invasive bladder cancer, characterized by a high mortality rate, in the Cox proportional hazards model. In conclusion, urine LF/Cr linked to TINs was a predictor of both invasive histology and prognosis in UCB. Urine LF/Cr is a potential biomarker reflecting the degree of malignancy in UCB. </p>

  • Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.

    Yuno T, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Mistunari K, Ohba K, Suda T, Saito S, Sakai H

    Anticancer research ( Anticancer Research )  40 ( 10 ) 5567 - 5575   2020.10 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    BACKGROUND/AIM: Stage-specific embryonic antigen-4 (SSEA-4) expression is associated with malignant aggressiveness and is useful as a marker for identifying cancer stem cells. Our aim was to assess the relationship between hormonal therapy and SSEA-4 expression in prostate cancer (PC). MATERIALS AND METHODS: SSEA-4 expression in paired specimens from PC patients who underwent neoadjuvant hormonal therapy (NHT) and radical prostatectomy (60 pre-NHT specimens and 60 post-NHT specimens) was evaluated using immunohistochemistry. Proliferation index (PI) and apoptotic index (AI) were also evaluated. RESULTS: Post-NHT tissues had significantly elevated SSEA-4 expression whereas anti-tumor effects of NHT were inversely correlated with SSEA-4 expression level. SSEA-4 expression in post-NHT tissues was significantly associated with biochemical recurrence-free survival. SSEA-4 expression in the post-NHT tissues was positively associated with PI and negatively done with AI. CONCLUSION: SSEA-4 is a potential therapeutic target for limiting the malignant potential in hormone-naïve PC when considering the use of NHT.

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -  2023.03 

    Direct: 3,400,000 (YEN)  Overheads: 1,020,000 (YEN)  Total: 4,420,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -  2023.03 

    Direct: 3,400,000 (YEN)  Overheads: 4,420,000 (YEN)  Total: 1,020,000 (YEN)

  • Research on markers expressed in high-grade prostate cancer

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2016.04  -  2019.03 

    Direct: 3,700,000 (YEN)  Overheads: 1,110,000 (YEN)  Total: 4,810,000 (YEN)

     View Summary

    We identified molecules related to the malignant potential of prostate cancer in prostate cancer cell lines. Those included enzyme protein (prostate cancer glycoprotein-enzyme: PCGP-enz), glyprotein (GP) related to glycolysis (PCGP-glyco),GP related to blood pressre (PCGP-bp), GP related to stress response (PCGP-stress), GP related to ubiquitin (PCGP-ub), GP commonly expressed in triple negative breast cancer (PCGP-br), GP commonly expressed in lung cancer (PCGP-lc), GP expressed in endoplasmic reticulum (PCGP-er), etc. Among those PCGP-lc and PCGP-er were significantly associated with higher Gleason score and PCGP-er was also significantly related to T stage using radical prostatectomy specimens. We also found stage-specific embryonic antigen-4 (SSEA-4) was significantly associated with the malignant behavior of prostate cancer using clinical samples.

  • Research on markers expressed in high-grade prostate cancer

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2016.04  -  2019.03 

    Investigator(s): Saito Seiichi, Miyata Yasuyoshi 

    Direct: 3,700,000 (YEN)  Overheads: 4,810,000 (YEN)  Total: 1,110,000 (YEN)

     View Summary

    We identified molecules related to the malignant potential of prostate cancer in prostate cancer cell lines. Those included enzyme protein (prostate cancer glycoprotein-enzyme: PCGP-enz), glyprotein (GP) related to glycolysis (PCGP-glyco),GP related to blood pressre (PCGP-bp), GP related to stress response (PCGP-stress), GP related to ubiquitin (PCGP-ub), GP commonly expressed in triple negative breast cancer (PCGP-br), GP commonly expressed in lung cancer (PCGP-lc), GP expressed in endoplasmic reticulum (PCGP-er), etc. Among those PCGP-lc and PCGP-er were significantly associated with higher Gleason score and PCGP-er was also significantly related to T stage using radical prostatectomy specimens. We also found stage-specific embryonic antigen-4 (SSEA-4) was significantly associated with the malignant behavior of prostate cancer using clinical samples.

  • Investigation of novel diagnostic biomarkers for prostate cancer based on RM2 antigen

    Grant-in-Aid for Young Scientists(B)

    Project Year: 2014.04  -  2017.03 

    Member: Seiichi, NAKANISHI Shotaro

    Direct: 2,900,000 (YEN)  Overheads: 870,000 (YEN)  Total: 3,770,000 (YEN)

     View Summary

    Although RM2 antigen is a new histological marker for prostate cancer that may reflect the tumor stage, the target proteins carrying RM2 antigen are yet unclear. To identify the target proteins, we focused on amino acid sequence of the 50kDa protein that reacts strongly to RM2 antibody. Histological expression of several candidate proteins in prostate cancer was significantly associated with Gleason score. Among these, urine level of a candidate protein in the patients with prostate cancer decreased compared to those with benign prostate. These results suggested that these candidate proteins would be useful as a new histological or urine marker of prostate cancer.

display all >>